Survival rates and related factors in men with hormone-refractory prostate cancer

Korean Journal of Urology

Volumn 50, Issue 7, 2009, Pages 649-655

  Hong, Koo Ha ^a   Chang, Jin Yun ^a   Seung, Soo Lee ^a   Dong, Gil Shin ^a   Lee, Wan ^a   Zeong, Zoo Lee ^a   Moon, Kee Chung ^a  

^a Pusan National University School of Medicine   (South Korea)

Author keywords

Prostatic neoplasms; Risk factors; Survival

Indexed keywords

HORMONE; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER STAGING; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; REFRACTORY PERIOD; SURVIVAL RATE; SURVIVAL TIME;

EID: 68449088398     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2009.50.7.649     Document Type: Article

References (18)

1. Korea Central Cancer Registry, Ministry for Health Welfare and Family Affairs. Annual report of the central cancer registry in Korea, National Cancer Center 2003-2005
2. Collette L, de Reijke TM, Schroder FH. Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892) Eur Urol 2003;44:182-189 (Pubitemid 36917001)
3. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68-80
4. Semeniuk RC, Venner PM, North S. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology 2006;68:565-569 (Pubitemid 44436503)
5. Eisenberger MA. Chemotherapy for hormone-resistant prostate cancer. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, editors. Campbell's urology. 7th ed. Philadelphia: Saunders; 1988;2648-2658
6. Oefelein MG, Agarwal PK, Resnick MI. Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. J Urol 2004;171:1525-1528 (Pubitemid 38365410)
7. Mike S, Harrison C, Coles B, Staffurth J, Wilt TJ, Mason MD. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev 2006;4:CD005247
8. Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002;20:3972-3982
9. Eisenberger MA, Crawford ED, Wolf M, Blumenstein B, McLeod DG, Benson R, et al. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036. Semin Oncol 1994;21:613-619
10. Matzkin H, Eber P, Todd B, van der Zwaag R, Soloway MS. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. Cancer 1992;70:2302-2309
11. Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventós CX, et al. Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer. Int J Biol Markers 2005;20:209-216 (Pubitemid 43103616)
12. Kwak C, Jeong SJ, Lee C, Jin RJ, Park TH, Lee SE. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer patients. Korean J Urol 2001;42:948-953
13. Park BJ, Lee YG, Ahn HK. Prognostic significance of prostate-specific antigen level two months after maximal androgen blockade in metastatic prostate cancer. Korean J Urol 2003;44:855-860
14. Kim KH, Seo YJ, Lee KS. The factors affecting prognosis in patients with metastatic prostate cancer after hormonal therapy. Korean J Urol 2004;45:24-28
15. Rozhansky F, Chen MH, Cox MC, Dahut W, Figg WD, D'Amico AV. Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. Cancer 2006;106:63-67 (Pubitemid 43032549)
16. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005;294:440-447 (Pubitemid 41124176)
17. Robinson D, Sandblom G, Johansson R, Garmo H, Aus G, Hedlund PO, et al. PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer. Urology 2008;72:903-907
18. Oudard S, Banu E, Scotte F, Banu A, Medioni J, Beuzeboc P, et al. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol 2007;18:1828-33 (Pubitemid 350111569)